NasdaqGS:PTCTBiotechs
PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing
PTC Therapeutics (PTCT) has drawn fresh attention after launching a $500 million private placement of 0% convertible senior notes due 2031, aimed at refinancing existing 2026 convertible debt and supporting general corporate needs.
See our latest analysis for PTC Therapeutics.
PTC Therapeutics shares have been volatile around the $78.53 level, with a 1-day share price return of 7.18% and a 90-day share price return of 17.08%, while the 1-year total shareholder return of 55.72% points to...